Get the Daily Brief
Latest Biotech News
10x Genomics pivots to clinical: CLIA lab and analysis partnerships
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana-Farber Cancer Institute, and the Cancer Research Institute while committing to build a CLIA‑certified lab...
Epidarex Capital raises $145M to back next‑gen UK‑US life science startups
Life‑science investor Epidarex Capital closed a $145 million first close on its fourth fund to target overlooked UK and US research corridors and seed the next generation of platform and...
Cultivated‑meat startup Innocent Meat raises €6M to build demo production
German cultivated‑meat startup Innocent Meat secured €6 million to develop a fully automated, software‑driven production system and to build a demonstration facility aimed at traditional meat...
FDA approvals: 27 in December brings 2025 total to 226
The U.S. Food and Drug Administration approved 27 drugs in December 2025—the month’s high—bringing the annual total to 226 approvals. That places 2025 just below 2024’s 228 approvals but well...
Industry sues IRA drug pricing: petitions reach Supreme Court
Novartis became the sixth drugmaker to bring a legal challenge to the U.S. Supreme Court over the Inflation Reduction Act’s drug pricing provisions, escalating a multi‑year industry battle over...
Parse and Graph partner to build massive functional immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic partnership to generate a large, multi‑context immune perturbation atlas by profiling hundreds of millions of cells from patients...
FDA draft nudges biosimilars away from efficacy trials – industry splits
The US Food and Drug Administration issued draft guidance recommending comparative analytical assessments (CAAs) as the primary route to demonstrate biosimilarity, advising that comparative...
AI designs anti‑CRISPRs: rapid Cas13 inhibitors emerge in eight weeks
Researchers at Monash University and the University of Melbourne reported de novo, AI‑designed anti‑CRISPR proteins (AIcrs) that inhibit Cas13a, validating hits in bacterial and human cells and...
10x Genomics pivots to clinic – CLIA lab build and hospital deals announced
10x Genomics signaled a strategic move beyond research tools by announcing clinical collaborations with Brigham & Women's Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute,...
Eclipsebio buys Terrain Bio – stacks AI RNA design with sequencing analytics
Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end platform that spans AI‑driven RNA design through manufacturing and high‑resolution sequencing validation. Eclipsebio said Terrain’s...
Worldwide Clinical Trials buys Catalyst – early‑phase oncology push via FSP
Worldwide Clinical Trials agreed to acquire UK‑based Catalyst Clinical Research to strengthen early‑phase oncology capabilities and add a functional service provider (FSP) model to its offerings....
Sarepta: three‑year Elevidys data claim growing efficacy despite prior safety and sales headwinds
Sarepta released three‑year follow‑up data for its Duchenne gene therapy Elevidys, reporting durable benefits on motor function measures versus historical controls and an expanding gap between...
Parse and Graph aim to profile hundreds of millions of immune cells – an atlas for AI drug discovery
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to build a large functional immune perturbation atlas by combining Graph’s patient‑derived disease models and...
Corxel closes $287M to advance oral GLP‑1 CX11 into pivotal testing
Corxel Pharmaceuticals raised $287 million in a Series D1 financing to accelerate development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...
Genmab halts enrollment in early trial of ProfoundBio asset after acquisition
Genmab paused patient enrollment in its Phase 1/2 study of GEN1286, a candidate acquired through its $1.8 billion buyout of ProfoundBio, citing an operational hold on the trial. The stop affects a...
Catalent to close Gosselies cell therapy site – manufacturing realignment continues
Catalent confirmed plans to close its cell therapy site in Gosselies, Belgium, attributing the decision to changing market dynamics and customer needs. The company is considering transitioning...
Worldwide Clinical Trials buys Catalyst – Early‑phase oncology push
Worldwide Clinical Trials agreed to acquire UK-based Catalyst Clinical Research to bolster early‑phase oncology capabilities and add functional service provider (FSP) offerings. The buyer,...
Eclipsebio acquires Terrain Bio: RNA design meets sequencing analytics
Eclipsebio acquired Terrain Bio to add machine‑learning RNA design and analytics to its sequencing‑first RNA genomics stack. Eclipsebio said the deal accelerates its plan to offer an end‑to‑end...
Parse and Graph Therapeutics pair up... build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic partnership to build a large, functional immune perturbation atlas profiling hundreds of millions of human cells. Graph will run...
Fortitude launches GLUE‑DAC platform – ADCs with degrader payloads
Fortitude Biomedicines launched with seed financing to develop antibody‑drug conjugates that use targeted protein degraders as payloads (GLUE‑DAC). The Waltham, Mass., startup said the approach...